Table 9.
Prevalence of metabolic syndrome according to NCEP-ATP III and AHA/NHLB definitions by previous antipsychotic treatment at baseline, Prev-AP, FAS, N = 642
| NCEP-ATP III | ||||
|---|---|---|---|---|
| Cohort | N | n | % | 95% CI |
| Missing | 4 | 0.6 | - | |
| Prev-Olz | 62 | 30 | 48.4 | 35.5 to 61.4 |
| Prev-Risp | 66 | 25 | 37.9 | 26.2 to 50.7 |
| Prev-Quet | 49 | 23 | 46.9 | 32.5 to 61.7 |
| Prev-Atyp | 102 | 45 | 44.1 | 34.3 to 54.3 |
| Prev-Typ | 90 | 38 | 42.2 | 31.9 to 53.1 |
| Prev-Comb | 107 | 52 | 48.6 | 38.8 to 58.5 |
| Prev-None | 162 | 34 | 21.0 | 15.0 to 28.1 |
| Total | 638 | 247 | 38.7 | 34.9 to 42.6 |
| AHA/NHLB | ||||
| Cohort | N | n | % | 95% CI |
| Missing | 4 | 0.6 | - | |
| Prev-Olz | 62 | 30 | 48.4 | 35.5 to 61.4 |
| Prev-Risp | 66 | 28 | 42.4 | 30.3 to 55.2 |
| Prev-Quet | 49 | 25 | 51.0 | 36.3 to 65.6 |
| Prev-Atyp | 102 | 50 | 49.0 | 39.0 to 59.1 |
| Prev-Typ | 90 | 39 | 43.3 | 32.9 to 54.2 |
| Prev-Comb | 107 | 61 | 57.0 | 47.1 to 66.5 |
| Prev-None | 162 | 40 | 24.7 | 18.3 to 32.1 |
| Total | 638 | 273 | 42.8 | 38.9 to 46.7 |
Abbreviations: AHA/NHLB = American Heart Association/National Heart, Lung and Blood Institute
CI = confidence interval, FAS = full analysis set; NCEP-ATP III = National Cholesterol Education Program, Adult Treatment Panel 3rd report; Prev-AP = previous antipsychotic treatment